Patent US5053485A successfully refreshed from Google Patents.
US5053485A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polymer lactide, method for preparing it and a composition containing it
Assignee: Purac Biochem BV
•
Filing: 1990-06-12
•
Granted: 1991-10-01
•
Expires: 2010-06-12
Abstract
Abstract A polymer lactide is prepared by the polymerization of meso-3,6-dimethyl-1,4-dioxane-2,5-dione or mesodilactide and, if desired, other monomers. The mesolactide monomer has preferably a free acid content of less than 1 meq/kg dilactide and is then polymerized in a manner known per se. The compositions containing polymesolactide obtained according to this process do not posess the typical characteristics of poly-DL-lactide, poly-D-lactide or poly-L-lactide. A shorter degradation time of a substrate based on the present polymer is unofficial for several purposes. The present polymers have a good biocompatibility and are thus suited for bone plates, clamps and sutures and controlled release of biologically active compounds. The present polylactides and/or copolymers thereof have the benefit of a good biodegradability, biocompatibility, non-toxicity and non-mutagenicity.
Inventors
- 👤 Jan Nieuwenhuis
- 👤 Arie C. Mol
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 21:26
CPC Classifications
C; C08; C08G; C08G63/00; C08G63/02; C08G63/06; C08G63/08; A; A61; A61L; A61L17/00; A61L17/06; A61L17/10; A61L17/12; A61L27/00; A61L27/14; A61L27/18; A61L31/00; A61L31/04; A61L31/06
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
26 words
A polymer composition, comprising: a surgical and pharmaceutical grade polymer lactide having at least two co-monomers therein, wherein at least one of said co-monomers is meso-3,6-dimethyl-1,4-dioxan-2,5-dione.
Claim 2
Dependent Claim
26 words
A polymer composition, comprising: a surgical and pharmaceutical grade polymer lactide having at least two co-monomers therein, wherein at least one of said co-monomers is meso-3,6-dimethyl-1,4-dioxan-2,5-dione.
Claim 3
Dependent Claim
21 words
The polymer composition according to claim 1 wherein said co-monomers other than meso-3,6-dimethyl-1,4-dioxan-2,5-dione comprise at most 99% of the polymer composition.
Claim 4
Dependent Claim
21 words
The polymer composition according to claim 2 wherein said co-monomers other than meso-3,6-dimethyl-1,4-dioxan-2,5-dione comprise at most 30% of the polymer composition.
Claim 5
Dependent Claim
34 words
The polymer composition according to claim 3 wherein said co-monomers other than meso-3,6-dimethyl-1,4-dioxan-2,5-dione are selected from the group consisting of L-lactide, glycolide, DL-lactide, γ- and δ-valerolactone, D-lactide and δ-caprolactam are used as other monomers.
Claim 6
Dependent Claim
20 words
The polymer composition according to claim 1 wherein said meso-3,6-dimethyl-1,4-dioxan-2,5-dione has a free acid content of less than 1 meq/kg.
Claim 7
Dependent Claim
28 words
Method for the preparation of a surgical and pharmaceutical grade polymer lactide, characterized in that meso-3,6-dimethyl-1,4-dioxan-2,5-dione is combined with at least one other co-monomer in the polymer composition.
Claim 8
Dependent Claim
28 words
Method for the preparation of a surgical and pharmaceutical grade polymer lactide, characterized in that meso-3,6-dimethyl-1,4-dioxan-2,5-dione is combined with at least one other co-monomer in the polymer composition.
Claim 9
Dependent Claim
29 words
Method according to claim 6 wherein a co-monomer selected from the group consisting of L-lactide, glycolide, DL-lactide, γ- and δ-valerolactone, D-lactide and ε-caprolactam is included within the polymer composition.
Claim 10
Dependent Claim
14 words
The method according to claim 6 wherein a biologically active substance is incorporated therein.
Claim 11
Dependent Claim
23 words
The polymer composition according to claims 5 wherein the co-monomers other than meso-3,6-dimethyl-1,4-dioxane-2,5-dione comprise not more than 99% by weight of the composition.
Claim 12
Dependent Claim
23 words
The polymer composition according to claim 9 wherein said co-monomers other than meso-3,6-dimethyl-1,4-dioxane-2,5-dione comprise not more than 50% by weight of the composition.
References Cited (Backward Citations)
DE1595085A1
Cited
US3636956A
Cited
US4033938A
Cited
US4743257A
Cited
US4743257C1
Cited
US4719246A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-30 | 1995-04-01 | 1995-10-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-30 | 1999-04-01 | 1999-10-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-30 | 2003-04-01 | 2003-10-01 | $7700.00 | Window Closed / Lapsed |